This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

COC and obesity

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

obesity and combined oral contraceptive pill

  • if BMI is >= 35 kg/m2 the risks associated with use of CHC generally outweigh the benefits (1)

Combined hormonal contraception (CHC)

  • most evidence suggests that effectiveness of combined oral contraception (COC) is not affected by body weight or BMI


  • limited evidence suggests a possible reduction in patch effectiveness in women weighing >=90 kg

  • limited evidence suggests that effectiveness of the vaginal ring is not affected by body weight or BMI

  • combined hormonal contraception (CHC) use is UKMEC 2 for use by women with BMI >= 30-34 kg/m2 and UKMEC 3 for women with BMI >=35 kg/m2

Weight gain with CHC


In the general population there is no evidence that use of CHC causes weight gain. There is nospecific evidence relating to weight gain with CHC use by women who are overweight or women with obesity

FSRH state (1):

  • women with obesity should be informed that:
    • risk of thrombosis increases with increasing BMI
    • current CHC use is associated with increased risk of VTE
    • current CHC use is associated with a small increased risk of myocardial infarction and ischaemic stroke
    • if BMI is >= 35 kg/m2 the risks associated with use of CHC generally outweigh the benefits

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.